Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSCW) Operating Margin (2020 - 2025)

Historic Operating Margin for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to 758.68%.

  • Ensysce Biosciences' Operating Margin fell 7775400.0% to 758.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 245.89%, marking a year-over-year decrease of 1031900.0%. This contributed to the annual value of 129.18% for FY2024, which is 3513500.0% up from last year.
  • As of Q3 2025, Ensysce Biosciences' Operating Margin stood at 758.68%, which was down 7775400.0% from 127.64% recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' Operating Margin registered a high of 18.86% during Q3 2024, and its lowest value of 3400.56% during Q2 2022.
  • In the last 5 years, Ensysce Biosciences' Operating Margin had a median value of 467.7% in 2023 and averaged 719.09%.
  • As far as peak fluctuations go, Ensysce Biosciences' Operating Margin plummeted by -33077400bps in 2022, and later skyrocketed by 29328600bps in 2023.
  • Over the past 5 years, Ensysce Biosciences' Operating Margin (Quarter) stood at 122.71% in 2021, then crashed by -253bps to 432.57% in 2022, then tumbled by -42bps to 612.72% in 2023, then skyrocketed by 55bps to 274.34% in 2024, then plummeted by -177bps to 758.68% in 2025.
  • Its Operating Margin was 758.68% in Q3 2025, compared to 127.64% in Q2 2025 and 149.08% in Q1 2025.